openPR Logo
Press release

Plexiform Neurofibroma Market Set to Grow According to Forecasts 2016 - 2024

06-02-2020 05:42 PM CET | Health & Medicine

Press release from: Transparency Market Research

Plexiform Neurofibroma Market Set to Grow According

One of the most commonly occurring single gene disorder affecting nervous system, neurofibromatosis type I or NF1 involves a number of skin abnormalities. Patients with NF1 have several tumors associated with nervous system and other body organs. These tumors are non-cancerous, known as neurofibromas, and are often formed on or under the skin, and even along the nerves throughout the body.

Read Report Overview - https://www.transparencymarketresearch.com/plexiform-neurofibroma-market.html

The most commonly observed tumor is cutaneous neurofibroma, plexiform neurofibroma market is characterized by the formation of small bumps under the skin, which proliferate in both size and number. Cutaneous neurofibromas though cause sensitivity and cosmetic issues, they cause negligible medical problems.

Another type of tumor that commonly affects NF1 patients is plexiform neurofibromas (pNFs) market. It is a benign tumor affecting peripheral nerves that follows the neural element proliferation. Around half of the NH1 affected patient population is usually prone to pNF. This type of tumor includes a range of cell types, such as mast cells, Schwann cells, macrophages, fibroblasts, neuronal axons, and perineural cells. It may also contain collagen and other similar extracellular matrix materials.

Plexiform neurofibrosis can occur anywhere in a body and tumors may continue to grow throughout the life span of a patient. If the neurofibroma converts into a malignant sarcoma or key organs of a body are compressed, it may also result in a deadly outcome. Among all the implictions of NF1, plexiform neurofibromas are the most exhaustive and widely observed. In addition to causing substantial morbidity, nPNF may result in disability, disfiguring, and functional impairment as well.

Request a Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14783

Rarely, plexiform neurofibromas may result in abnormal functioning of eyes, dysplasias, cognitive deficits, and cardiovascular disorders. Moreover, there are higher chances of acquiring gliomas, leukemias, neuroendocrine tumors, and sometimes breats cancer in females over 50 years of age.

As pNFs may affect any part of a human body, they generally lead to clinical complications. Those occurred in the areas near neck or head are especially complicated because they result in a range of functional deficits and facial feature disfiguring. Large tumor resections often come with a risk of functional destruction and neurological complications.

MRI and CT scans are used for primary diagnosis of pNFs. When it comes to selecting the right treatment option, medication is not considered the only option as it is proved to be inefficient in treating plexiform neurofibroma. Surgery is the only relatively effective therapy available today. Surgical excision starts with de-bulking, and does not assure cure. Tumors continue to regrow post-surgery and patients have to undergo multiple surgical interventions. Rapid tumor growth, tumor size and location, tumor's microscopic extension, and neural involvement collectively make it difficult to implement a surgical procedure.

Request for Analysis of COVID19 Impact - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=14783

Combination chemotherapy is already being used against plexiform neurofibromas. Drugs, which are used in combination with chemotherapy serve to prevent the proliferation of tumors. Sometimes, tumors may also die. However, the efficacy of combination therapy is not considered a completely reliable option to treat pNF patients.

Other possible methods of treatment are being researched on but nothing substantial has been found yet, in terms of plexiform neurofibroma treatment. Being associated with neurofibromatosis type I, pNFs either reoccur or transform in a malignant stage. Moreover, the tumors are non-radioactive and thus chemotherapy also shows a limited impact. Evaluating clinical trials is quite challenging in case of plexiform neurofibromas, as they develop in an unpredictable manner, making it difficult to examine the objective response. Emergence of innovative techniques of neuroimaging might play a vital role in clinical trials and help to discover highly potential treatment options thereby.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Plexiform Neurofibroma Market Set to Grow According to Forecasts 2016 - 2024 here

News-ID: 2065294 • Views:

More Releases from Transparency Market Research

RF Chip Inductor Market Size to Reach over USD 1.8 billion by 2031 - Transparency Market Research Inc.
RF Chip Inductor Market Size to Reach over USD 1.8 billion by 2031 - Transparenc …
RF Chip Inductor Market are essential components in various electronic devices, providing inductance and functioning as filters, oscillators, and transformers. They play a crucial role in ensuring the efficiency and performance of RF circuits. With the rapid advancement in telecommunications, consumer electronics, and automotive industries, the demand for RF chip inductors has seen a significant rise. These components are integral in applications such as smartphones, IoT devices, and automotive electronics,
Solid Tires Market Expected to Witness Impressive Growth at a 8.1% CAGR by 2031
Solid Tires Market Expected to Witness Impressive Growth at a 8.1% CAGR by 2031
The latest research study released by Transparency Market Research on "Solid Tires Market Forecast to 2023-2031 ″ research provides accurate economic, global, and country-level predictions and analyses. Solid Tires market is estimated to attain a valuation of US$ 760.0 Mn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 8.1% during
Automotive Cyber security Market Sales Estimated to Hit USD 10.5 Billion by 2031| Says Transparency Market Research
Automotive Cyber security Market Sales Estimated to Hit USD 10.5 Billion by 2031 …
The latest research study released by Transparency Market Research on "𝐀𝐮𝐭𝐨𝐦𝐨𝐭𝐢𝐯𝐞 𝐂𝐲𝐛𝐞𝐫 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 𝟐𝟎𝟐𝟑-𝟐𝟎𝟑𝟏 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Automotive Cyber security industry, as
Ready-mix Concrete Market to Witness Exponential Growth with a CAGR of 6.1% from 2022 to 2031: TMR Study
Ready-mix Concrete Market to Witness Exponential Growth with a CAGR of 6.1% from …
The latest research study released by Transparency Market Research on "𝐑𝐞𝐚𝐝𝐲-𝐦𝐢𝐱 𝐂𝐨𝐧𝐜𝐫𝐞𝐭𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 𝟐𝟎𝟐𝟑-𝟐𝟎𝟑𝟏 ″ research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Ready-mix Concrete industry, as well as

All 5 Releases


More Releases for NF1

Neurofibromatosis Type 1 Market Expected to Gain Momentum Through 2034, Accordin …
The Key Neurofibromatosis Type 1 Companies in the market include - AstraZeneca and Merck, SpringWorks Therapeutics, Healx, Pasithea Therapeutics, Fosun Pharmaceutical, NFlection Therapeutics, and others. DelveInsight's "Neurofibromatosis Type 1 Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Neurofibromatosis Type 1, historical and forecasted epidemiology as well as the Neurofibromatosis Type 1 market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and
The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 …
The the emergence of new transformative NF1-PN treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics), and others. The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks
Strong Growth Ahead: Neurofibromatosis Type 1 Market Size To Grow At Arecord 9.6 …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. How Big Is the Neurofibromatosis Type 1 Market Size Expected to Be by 2034? In recent times, the growth of the neurofibromatosis type 1 (NF1) market size has been robust. The market is predicted to escalate from $8.06 billion in 2024 to $8.86 billion in 2025, exhibiting a compound annual growth rate
Neurofibromatosis Type 1 Pipeline: Emerging Targeted Therapies and Gene-Based Ap …
The treatment landscape for Neurofibromatosis Type 1 (NF1), a rare genetic disorder characterized by nerve sheath tumors, skin changes, and other systemic complications, is undergoing a pivotal transformation. Historically limited to symptomatic and surgical management, recent advances are driving the development of disease-modifying therapies that target the underlying genetic and molecular mechanisms. With no curative treatments available, there is a growing focus on MEK inhibitors, RAS/MAPK pathway modulators, and gene
In-Depth Analysis of the Neurofibromatosis Type 1 Market: Growth Opportunities, …
What industry-specific factors are fueling the growth of the neurofibromatosis type 1 market? The rising occurrence of spontaneous (de novo) mutations is expected to boost the growth of the neurofibromatosis type 1 (NF1) market. Spontaneous mutations occur due to errors in DNA replication or environmental factors, rather than being inherited. In NF1, the high mutation rate in the NF1 gene contributes to new cases, even without a family history. For example,
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The ongoing NF1-PN drug development pipeline features additional MEK inhibitors, including Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Additionally, HLX-1502 (Healx) is an emerging investigational therapy that provides a novel treatment approach for NF1 patients. The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new